{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:59:27Z","timestamp":1783699167296,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.amjmed.2016.07.038","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T23:16:15Z","timestamp":1477437375000},"page":"173-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Role of Niacin in Current Clinical Practice: A Systematic Review"],"prefix":"10.1016","volume":"130","author":[{"given":"Aakash","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuram","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Virmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toishi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Kostis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Sikorskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjmed.2016.07.038_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIR.0000000000000157","article-title":"Executive summary: heart disease and stroke statistics-2015 update: a report from the American Heart Association","volume":"131","year":"2015","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjmed.2016.07.038_bib2","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease\u2014the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"},{"issue":"24","key":"10.1016\/j.amjmed.2016.07.038_bib3","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.amjmed.2016.07.038_bib5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2014.08.007","article-title":"Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study","volume":"168","author":"Andersson","year":"2014","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.amjmed.2016.07.038_bib6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.amjmed.2016.07.038_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"9493","key":"10.1016\/j.amjmed.2016.07.038_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"25 suppl 2","key":"10.1016\/j.amjmed.2016.07.038_bib10","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjmed.2016.07.038_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"5","key":"10.1016\/j.amjmed.2016.07.038_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.amjmed.2016.07.038_bib14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2016.07.038_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-153-12-201012210-00006","article-title":"Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk","volume":"153","author":"Jafri","year":"2010","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.amjmed.2016.07.038_bib16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.jacc.2013.07.051","volume":"62","author":"Acharjee","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.amjmed.2016.07.038_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199108083250601","article-title":"A\u00a0prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction","volume":"325","author":"Stampfer","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib20","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2016.07.038_bib22","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.amjmed.2016.07.038_bib23","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2016.07.038_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2016.07.038_bib25","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib26","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2016.07.038_bib27","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.amjmed.2016.07.038_bib28","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A\u00a0randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.amjmed.2016.07.038_bib31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2016.07.038_bib32","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib33","doi-asserted-by":"crossref","first-page":"1564e72","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib34","first-page":"1615","article-title":"Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification","volume":"122","author":"Sang","year":"2009","journal-title":"Chin Med J (Engl)"},{"issue":"14","key":"10.1016\/j.amjmed.2016.07.038_bib35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.07.038_bib36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2016.07.038_bib37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22","volume":"29","author":"Ray","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9738","key":"10.1016\/j.amjmed.2016.07.038_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2016.07.038_bib39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1074248410361337","article-title":"Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease","volume":"15","author":"Duggal","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2016.07.038_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2016.07.038_bib42","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.amjmed.2016.07.038_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2016.07.038_bib44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/2047487315572920","article-title":"The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: implications for coronary atheroma progression and cardiovascular events","volume":"23","author":"Puri","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjmed.2016.07.038_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.07.038_bib46","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.amjmed.2016.07.038_bib47","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jacc.2013.07.025","article-title":"The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality","volume":"62","author":"Khera","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.amjmed.2016.07.038_bib48","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2016.07.038_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/ATVBAHA.115.306834","article-title":"Extended-release niacin\/laropiprant improves overall efficacy of postprandial reverse cholesterol transport","volume":"36","author":"El Khoury","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.amjmed.2016.07.038_bib50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1161\/ATVBAHA.115.306268","article-title":"Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects","volume":"36","author":"Ronsein","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.amjmed.2016.07.038_bib51","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","volume":"128","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.07.038_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2009.08.045","article-title":"Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin","volume":"209","author":"Digby","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2016.07.038_bib53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.amjmed.2016.07.038_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2016.07.038_bib55","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316310580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934316310580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:11:27Z","timestamp":1757581887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934316310580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0002934316310580"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.07.038","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Niacin in Current Clinical Practice: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}